JO
OREX

John Overdeck’s Orexigen Therapeutics, Inc. OREX Stock Holding History

John Overdeck’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-38,937
Closed -$3.05M – 3363
2015
Q1 		$3.05M Buy
+38,937
New +$2.42M 0.01% 947
2014
Q1 		– Sell
-12,329
Closed -$694K – 2583
2013
Q4 		$694K Buy
+12,329
New +$693K ﹤0.01% 1515

Other funds holding OREX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

John Overdeck's OREX Position: Q2 2015 in Review

John Overdeck sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2015, closing a stake of 38,937 shares — an estimated $3.05M sold.

John Overdeck first reported a position in OREX in Q4 2013 and held it in 2 quarters. The position peaked at $3.05M in Q1 2015. 161 funds tracked by Wall St. Rank hold OREX as of Q2 2015.

  • John Overdeck reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
  • John Overdeck sold 38,937 Orexigen Therapeutics, Inc. shares in Q2 2015, an estimated $3.05M.
  • John Overdeck first reported a position in Orexigen Therapeutics, Inc. in Q4 2013 and held it in 2 quarters.
  • John Overdeck's Orexigen Therapeutics, Inc. position peaked at $3.05M in Q1 2015.
  • 161 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2015.

Based on Two Sigma Investments's 13F filing for Q2 2015, filed 14 Aug 2015.